Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China
To comprehensively assess the safety and difference of two types of EV71 vaccines: EV71-Vero, produced using Vero cells and EV71-H2, using human diploid cells. Our research included children of the recommended age who voluntarily received the EV71 vaccine in Hebei Province from 2019 to 2023. Detaile...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2458831 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565167244705792 |
|---|---|
| author | Yiqing Zhu Yihan Wang Jinghui Wang Yafei Wang Li Sun Shiheng Cui Jing Li Yu Guo |
| author_facet | Yiqing Zhu Yihan Wang Jinghui Wang Yafei Wang Li Sun Shiheng Cui Jing Li Yu Guo |
| author_sort | Yiqing Zhu |
| collection | DOAJ |
| description | To comprehensively assess the safety and difference of two types of EV71 vaccines: EV71-Vero, produced using Vero cells and EV71-H2, using human diploid cells. Our research included children of the recommended age who voluntarily received the EV71 vaccine in Hebei Province from 2019 to 2023. Detailed data on adverse events following immunization (AEFI) were collected, analyzed and compared for EV71-Vero and EV71-H2 vaccines. With 477 AEFI reported, the reported rate was 14.21 per 100,000 doses. Most cases occurred in infants under one year of age (45.91%). No significant differences in the AEFI reported rate were found between two types of EV71 vaccines across various demographic. However, a higher number of AEFI was reported in children under 1-year old following EV71-Vero compared to EV71-H2 with a reversal in 4–5 years- group (χ2 = 13.90, p = .01). The prognosis of cured took higher proportion for EV71-Vero than for EV71-H2 while inversely with improved outcome. The EV71 vaccine is advisable recommend to the appropriate age children to prevent EV7l infection. Both the EV71-Vero and EV71-H2 vaccines have good safety profiles. The reported AEFI, primarily high fever and allergic reactions, showed no significant differences in reported rates or case characteristics between the two types. |
| format | Article |
| id | doaj-art-6069686433bf42f2bb30091f42bfb4bc |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-6069686433bf42f2bb30091f42bfb4bc2025-02-03T01:09:11ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2458831Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in ChinaYiqing Zhu0Yihan Wang1Jinghui Wang2Yafei Wang3Li Sun4Shiheng Cui5Jing Li6Yu Guo7Department of Immunization Management, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei Province, ChinaDepartment of Immunization Management, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei Province, ChinaDepartment of Immunization Management, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei Province, ChinaDepartment of Immunization Management, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei Province, ChinaDepartment of Immunization Management, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei Province, ChinaDepartment of Immunization Management, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei Province, ChinaDepartment of Immunization Management, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei Province, ChinaDepartment of Immunization Management, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei Province, ChinaTo comprehensively assess the safety and difference of two types of EV71 vaccines: EV71-Vero, produced using Vero cells and EV71-H2, using human diploid cells. Our research included children of the recommended age who voluntarily received the EV71 vaccine in Hebei Province from 2019 to 2023. Detailed data on adverse events following immunization (AEFI) were collected, analyzed and compared for EV71-Vero and EV71-H2 vaccines. With 477 AEFI reported, the reported rate was 14.21 per 100,000 doses. Most cases occurred in infants under one year of age (45.91%). No significant differences in the AEFI reported rate were found between two types of EV71 vaccines across various demographic. However, a higher number of AEFI was reported in children under 1-year old following EV71-Vero compared to EV71-H2 with a reversal in 4–5 years- group (χ2 = 13.90, p = .01). The prognosis of cured took higher proportion for EV71-Vero than for EV71-H2 while inversely with improved outcome. The EV71 vaccine is advisable recommend to the appropriate age children to prevent EV7l infection. Both the EV71-Vero and EV71-H2 vaccines have good safety profiles. The reported AEFI, primarily high fever and allergic reactions, showed no significant differences in reported rates or case characteristics between the two types.https://www.tandfonline.com/doi/10.1080/21645515.2025.2458831Enterovirus 71 vaccinevaccine safetyadverse events following immunizationpost-marketing safetyAEFI surveillance |
| spellingShingle | Yiqing Zhu Yihan Wang Jinghui Wang Yafei Wang Li Sun Shiheng Cui Jing Li Yu Guo Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China Human Vaccines & Immunotherapeutics Enterovirus 71 vaccine vaccine safety adverse events following immunization post-marketing safety AEFI surveillance |
| title | Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China |
| title_full | Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China |
| title_fullStr | Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China |
| title_full_unstemmed | Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China |
| title_short | Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China |
| title_sort | adverse events following immunization surveillance on two types of enterovirus 71 vaccines a real world comparative study in china |
| topic | Enterovirus 71 vaccine vaccine safety adverse events following immunization post-marketing safety AEFI surveillance |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2458831 |
| work_keys_str_mv | AT yiqingzhu adverseeventsfollowingimmunizationsurveillanceontwotypesofenterovirus71vaccinesarealworldcomparativestudyinchina AT yihanwang adverseeventsfollowingimmunizationsurveillanceontwotypesofenterovirus71vaccinesarealworldcomparativestudyinchina AT jinghuiwang adverseeventsfollowingimmunizationsurveillanceontwotypesofenterovirus71vaccinesarealworldcomparativestudyinchina AT yafeiwang adverseeventsfollowingimmunizationsurveillanceontwotypesofenterovirus71vaccinesarealworldcomparativestudyinchina AT lisun adverseeventsfollowingimmunizationsurveillanceontwotypesofenterovirus71vaccinesarealworldcomparativestudyinchina AT shihengcui adverseeventsfollowingimmunizationsurveillanceontwotypesofenterovirus71vaccinesarealworldcomparativestudyinchina AT jingli adverseeventsfollowingimmunizationsurveillanceontwotypesofenterovirus71vaccinesarealworldcomparativestudyinchina AT yuguo adverseeventsfollowingimmunizationsurveillanceontwotypesofenterovirus71vaccinesarealworldcomparativestudyinchina |